Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q2 2022 · 10-Q
Revenue$179.30M$179.30M−5.3% vs Q2 2021 Net Income-$14.10M-$14.10MN/M vs Q2 2021 EPS Diluted-$0.18-$0.18N/M vs Q2 2021 Operating Income-$17,800,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$56,400,000N/M Margins · derivedOperating margin-9.9%+1.1 pt vs Q2 2021
Net margin-7.9%−5.4 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 5, 2022 · 36 d after period end